ARWR · Nasdaq · CIK 0000879407

ARROWHEAD PHARMACEUTICALS, INC.

ARROWHEAD PHARMACEUTICALS, INC.’s most recent SEC filing in our snapshot is a Form 4 filed on Aug 20, 2026. In fiscal 2025 (year ended Sep 30, 2025) it reported revenue of $829.4M and net income of -$1.6M, according to its XBRL data on EDGAR. Its EDGAR record lists 30 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025

$829.4M

Net income, FY2025

-$1.6M

Form 4 filings on record, past 12 months

Company overview

Legal name (as filed): ARROWHEAD PHARMACEUTICALS, INC.
Ticker: ARWR
SEC Central Index Key (CIK): 0000879407
Industry (SIC): Pharmaceutical Preparations (code 2834)
Business address: PASADENA, CA
State or country of incorporation: DE
Fiscal year ends: September 30
SEC filer category: Large accelerated filer
Position in SEC ticker list: #1025 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from ARROWHEAD PHARMACEUTICALS, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue

Net income

ARWR annual results
Item	FY2021 ended Sep 30, 2021	FY2022 ended Sep 30, 2022	FY2023 ended Sep 30, 2023	FY2024 ended Sep 30, 2024	FY2025 ended Sep 30, 2025
Revenue	$138.3M	$243.2M	$240.7M	$3.6M	$829.4M
Net income	-$140.8M	-$176.1M	-$205.3M	-$599.5M	-$1.6M
Diluted EPS	-$1.36	-$1.67	-$1.92	-$5.00	-$0.01
Total assets	$710.1M	$691.9M	$765.6M	$1.1B	$1.4B
Cash and equivalents	$184.4M	$108.0M	$110.9M	$102.7M	$226.5M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ARWR latest annual, quarterly, current and proxy reports
Filed	Form	What it is	Original
Nov 25, 2025	10-K	Annual report· period Sep 30, 2025	Document · Index
Aug 4, 2026	10-Q	Quarterly report· period Jun 30, 2026	Document · Index
Aug 4, 2026	8-K	Results of operations· period Aug 4, 2026	Document · Index
Jan 27, 2026	DEF 14A	Definitive proxy statement· period Jan 26, 2026	Document · Index

Recent SEC filings

The 40 newest documents filed by or about ARROWHEAD PHARMACEUTICALS, INC., by form type:

4 ×78-K ×7144 ×6SCHEDULE 13G/A ×610-Q ×3144/A ×3SCHEDULE 13G ×33 ×1S-8 ×1ARS ×1DEFA14A ×1DEF 14A ×1

ARWR recent filings
Filed	Form	What it is	Original
Aug 20, 2026	4	Statement of changes in beneficial ownership (insider trade)· period Aug 18, 2026	Document · Index
Aug 20, 2026	4	Statement of changes in beneficial ownership (insider trade)· period Aug 18, 2026	Document · Index
Aug 18, 2026	144	Notice of proposed sale of securities	Document · Index
Aug 18, 2026	144	Notice of proposed sale of securities	Document · Index
Aug 14, 2026	SCHEDULE 13G/A	Passive beneficial ownership report (over 5%)	Document · Index
Aug 4, 2026	8-K	Results of operations· period Aug 4, 2026	Document · Index
Aug 4, 2026	10-Q	Quarterly report· period Jun 30, 2026	Document · Index
Jul 31, 2026	SCHEDULE 13G/A	Passive beneficial ownership report (over 5%)	Document · Index
Jul 27, 2026	SCHEDULE 13G/A	Passive beneficial ownership report (over 5%)	Document · Index
Jun 17, 2026	4	Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026	Document · Index
Jun 17, 2026	3	Initial statement of beneficial ownership· period Jun 15, 2026	Document · Index
Jun 16, 2026	8-K	Director or officer change· period Jun 12, 2026	Document · Index
May 19, 2026	144/A	144/A	Document · Index
May 19, 2026	144/A	144/A	Document · Index
May 19, 2026	144/A	144/A	Document · Index
May 14, 2026	4	Statement of changes in beneficial ownership (insider trade)· period May 12, 2026	Document · Index
May 12, 2026	144	Notice of proposed sale of securities	Document · Index
May 7, 2026	S-8	Registration of employee benefit plan securities	Document · Index
May 7, 2026	10-Q	Quarterly report· period Mar 31, 2026	Document · Index
May 7, 2026	8-K	Results of operations· period May 7, 2026	Document · Index
May 6, 2026	SCHEDULE 13G	Passive beneficial ownership report (over 5%)	Document · Index
Apr 29, 2026	SCHEDULE 13G	Passive beneficial ownership report (over 5%)	Document · Index
Apr 28, 2026	SCHEDULE 13G	Passive beneficial ownership report (over 5%)	Document · Index
Apr 24, 2026	SCHEDULE 13G/A	Passive beneficial ownership report (over 5%)	Document · Index
Apr 24, 2026	4	Statement of changes in beneficial ownership (insider trade)· period Apr 23, 2026	Document · Index
Apr 24, 2026	4	Statement of changes in beneficial ownership (insider trade)· period Apr 22, 2026	Document · Index
Apr 23, 2026	144	Notice of proposed sale of securities	Document · Index
Apr 22, 2026	144	Notice of proposed sale of securities	Document · Index
Mar 26, 2026	SCHEDULE 13G/A	Passive beneficial ownership report (over 5%)	Document · Index
Mar 20, 2026	8-K	Shareholder vote results· period Mar 19, 2026	Document · Index
Mar 9, 2026	4	Statement of changes in beneficial ownership (insider trade)· period Mar 5, 2026	Document · Index
Mar 5, 2026	144	Notice of proposed sale of securities	Document · Index
Feb 5, 2026	10-Q	Quarterly report· period Dec 31, 2025	Document · Index
Feb 5, 2026	8-K	Results of operations· period Feb 5, 2026	Document · Index
Jan 27, 2026	ARS	ARS· period Jan 26, 2026	Document · Index
Jan 27, 2026	DEFA14A	Additional proxy soliciting materials	Document · Index
Jan 27, 2026	DEF 14A	Definitive proxy statement· period Jan 26, 2026	Document · Index
Jan 21, 2026	SCHEDULE 13G/A	Passive beneficial ownership report (over 5%)	Document · Index
Jan 12, 2026	8-K	Material agreement; New financial obligation· period Jan 12, 2026	Document · Index
Jan 9, 2026	8-K	Material agreement; Other events· period Jan 7, 2026	Document · Index

Insider filing activity

30 Form 4 filings appear in ARROWHEAD PHARMACEUTICALS, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000879407 and XBRL company facts. ARROWHEAD PHARMACEUTICALS, INC. on EDGAR.
Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.